Valiant Laboratories Ltd
Valiant Laboratories Ltd (VALIANTLAB) last traded at ₹105, a market capitalisation of ₹573 crore, on a P/E of 35.8. Over the past 52 weeks the stock has ranged between ₹49.5 and ₹106. Valiant Laboratories Ltd last reported results for the quarter ended Jun 2026, with sales of ₹115 crore and net profit of ₹21 crore. Figures are as of 25 Aug 2026 and are not real time.
Valiant Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Valiant Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹115 cr, up 144.7% from ₹47 cr a year earlier. Net profit was ₹21 cr, up 950.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 35 | 58 | 47 | 46 | 52 | 92 | 115 |
| Expenses | 28 | 35 | 54 | 44 | 46 | 53 | 87 | 86 |
| Operating profit | -7 | 1 | 4 | 2 | 0 | -1 | 5 | 29 |
| OPM % | -31% | 1.8% | 7% | 5% | 0.2% | -1.7% | 5% | 25% |
| Other income | 3 | 2 | -2 | 1 | 1 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| Profit before tax | -4 | 2 | 1 | 2 | 0 | -3 | 1 | 26 |
| Tax % | 21% | -44% | 26% | 26% | 25% | 136% | -68% | 19% |
| Net profit | -5 | 2 | 1 | 2 | 0 | -7 | 2 | 21 |
| EPS (₹) | -0.87 | 0.43 | 0.13 | 0.34 | 0.04 | -1.30 | 0.32 | 3.88 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Valiant Laboratories Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 334 | 182 | 133 | 237 | 306 |
| Operating profit | 35 | -8 | -5 | 6 | 33 |
| OPM % | 11% | -4.6% | -3.5% | 2.7% | 11% |
| Net profit | 29 | 0 | -2 | -3 | 16 |
| EPS (₹) | 7.13 | 0.06 | -0.41 | -0.60 | 2.94 |
TTM is the trailing twelve months to the most recent quarter.
Valiant Laboratories Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -11%
- TTM
- 90%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 12208%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 16%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -1%
- Last Year
- -1%
Valiant Laboratories Ltd shareholding pattern
Promoters held 74.94% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.00% and DIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| FIIs | 0.00% | 0.00% | 0.64% | 0.63% | 0.02% | 0.01% | 0.20% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.46% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 25.06% | 25.06% | 24.42% | 23.97% | 25.05% | 25.05% | 24.87% | 25.06% |
| No. of shareholders | 15,189 | 15,692 | 15,036 | 14,432 | 15,075 | 14,910 | 14,657 | 14,341 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Valiant Laboratories Ltd
Valiant Laboratories Ltd corporate filings
- Copy of Newspaper Publication of Financial Results for the quarter ended June 30, 2026.Company Updatehigh impact
Cruxal's analysis: Valiant Laboratories Limited has announced its audited financial results for the quarter…
Read the full analysis - Monitoring Agency Report for the quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Valiant Laboratories has filed its Monitoring Agency Report for the quarter ended June…
Read the full analysis - Opening of a new Corporate Office of the CompanyCompany Updatelow impact
Cruxal's analysis: Valiant Laboratories Ltd has formally announced the opening of a new corporate office…
Read the full analysis - Change in the Registered Office address of the Company, subject to the approval of shareholders and other Statutory Authorities.Company Updatelow impact
Cruxal's analysis: Valiant Laboratories Ltd has announced a proposal to change its registered office…
Read the full analysis - Re-appointment of Managing Director, Independent Director and Continuation of Directorship of Non- Executive Director.Company Updatemedium impact
Cruxal's analysis: Valiant Laboratories Limited has announced an additional investment of up to 60 crore in…
Read the full analysis - Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.Board Meetinghigh impact
Cruxal's analysis: Valiant Laboratories Limited has announced its audited financial results for the quarter…
Read the full analysis - Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve financial results for ....Board Meetinglow impact
Cruxal's analysis: Valiant Laboratories Limited has formally intimated the stock exchanges regarding a Board…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Valiant Laboratories Ltd
Cruxal reads every Valiant Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.